Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
CMS innovation center to expand team focused on drug prices
To help with new pilot models aimed at lowering drug costs across Medicaid and Medicare, CMS’ innovation center is ramping up staff. “We are on


